<DOC>
	<DOCNO>NCT01729819</DOCNO>
	<brief_summary>The purpose study investigate efficacy combine tolterodine desmopressin compare tolterodine monotherapy treatment woman overactive bladder nocturia term reduction nocturnal void 3 month treatment</brief_summary>
	<brief_title>Interventional Clinical Trial Patients Overactive Bladder With Nocturia Women</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Nocturia</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>Written inform consent prior performance trialrelated activity Female sex , least 18 year age ( time write consent ) Nocturia overactive bladder symptom present â‰¥6 month prior trial entry ( patientreported ) At least 2 nocturnal void night document 2 diary period screen . A mean least 8 daytime void per day 3 day minimum least 6 daytime void day document 2 diary period screen . At least 1 urgency episode 24 hour document 2 diary period screen . Each diary period consist 3 consecutive day , least 14 day period . Evidence severe void dysfunction define : More 10 nocturnal void per 24 hour document day diary period screen . More 20 daytime void per 24 hour document day diary period screen . Genitourinary tract pathology investigator 's opinion responsible urgency urinary incontinence e.g. , symptomatic recurrent urinary tract infection , interstitial cystitis , bladder relate pain , stone bladder urethra cause symptom Current history within 5 year low urologic malignancy ( e.g. , bladder cancer ) , low urinary tract surgery , previous pelvic irradiation , severe neurological disease affect bladder function muscle strength ( e.g. , multiple sclerosis , Parkinson 's disease , spinal cord injury , spina bifida ) Symptoms severe stress urinary incontinence opinion investigator Urinary retention post void residual volume excess 150 mL confirm bladder ultrasound perform suspicion urinary retention Habitual psychogenic polydipsia ( fluid intake result urine production exceed 40 mL/kg/24 hour ) mean volume void per void 350 mL one 24hour period assess screen diary Central nephrogenic diabetes insipidus Syndrome inappropriate antidiuretic hormone ( SIADH ) Gastric retention Myasthenia gravis Uncontrolled narrowangle glaucoma Suspicion evidence cardiac failure Uncontrolled clinically relevant ( judgement investigator ) hypertension diabetes mellitus History and/or current treatment obstructive sleep apnoea Hyponatraemia : Serum sodium level must 135 mmol/L Evidence potential renal impairment : Serum creatinine must within normal laboratory reference interval AND estimate glomerular filtration rate must equal 50 mL/min Hepatic and/or biliary disease : Aspartate aminotransferase and/or alanine aminotransferase level must twice upper limit normal range . Total bilirubin level must 1.5 mg/dL Pregnancy , breastfeeding , plan become pregnant period trial . Women reproductive age must documentation reliable method contraception . All pre perimenopausal woman perform pregnancy test . Amenorrhea 12 month duration base report date last menstrual period sufficient documentation postmenopausal status require pregnancy test Known alcohol substance abuse ; work lifestyle may interfere regular nighttime sleep e.g. , shift worker ; medical condition , laboratory abnormality , psychiatric condition , mental incapacity , illiteracy language barrier , judgement investigator , would impair participation trial Known suspect hypersensitivity active ingredient excipients investigational medicinal product use trial Previous participation desmopressin trial within last 5 year Use prohibit therapy , define protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>